Givosiran is an ALAS1-directed small interfering RNA (siRNA) molecule first approved in 2019 by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with AIP [26]. Here, ALAS1 is linked to autoimmune pancreatitis.